RA Drug Olumiant May Help Treat Atopic Dermatitis Late Stage Study Everyday Health

RA Drug Olumiant May Help Treat Atopic Dermatitis Late Stage Study Everyday Health

RA Drug Olumiant May Help Treat Atopic Dermatitis: Late-Stage Study Everyday Health MenuNewslettersSearch Eczema News

RA Drug Olumiant May Help Treat Atopic Dermatitis a Late-Stage Study Finds

This year, Eli Lilly and Company plan to submit the drug for U.S. approval for treating this type of eczema. By Becky UphamJanuary 31, 2020Everyday Health ArchiveFact-CheckedThe FDA has approved Olumiant to treat RA.Eli Lilly; iStockPeople who manage life with atopic dermatitis (AD) are one step closer to having another treatment option. Eli Lilly and Company and Incyte announced in late January that the rheumatoid arthritis (RA) drug Olumiant (baricitinib) met the primary endpoint in BREEZE-AD5, a phase 3 randomized placebo-controlled study evaluating the safety and efficacy of the drug for the treatment of adults with moderate to severe atopic dermatitis. The primary endpoint of the trial was defined by the proportion of participants who achieved a 75 percent or greater change from baseline in their eczema area and severity index (EASI-75) at week 16. An EASI score is a standardized way that doctors evaluate atopic dermatitis, dividing the skin into four regions and then rating the intensity of redness, thickness, scratching, and lichenification (meaning lined skin, furrowing, and prurigo nodules). Olumiant is part of a class of drugs known as JAK inhibitors, which belong to a category of drugs called disease-modifying antirheumatic drugs (DMARDs). Currently, Olumiant is approved to treat RA but not atopic dermatitis, the most common type of eczema. Dupixent (dupilumab) is the only JAK inhibitor that’s been approved for treating atopic dermatitis, but there are several other drugs in the pipeline. Those include abrocitinib, and lebrikizumab, an anti-IL-13 antibody medication, which could be available in the future if they have successful trials. “I have an atopic dermatitis and itch specialty clinic here at Johns Hopkins, and so I treat a lot of people with atopic dermatitis, and this is really an exciting time,” says Shawn Kwatra, MD, an assistant professor of dermatology at Johns Hopkins Medicine in Baltimore. “For many years we didn’t have good treatment options for these patients.” RELATED: A Complete Guide to Treating Eczema

More Options May Mean Fewer Side Effects for People With Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory skin disease that causes rashes and areas of itchy skin. Close to 16.5 million adults have atopic dermatitis, with 6.6 million reporting moderate to severe symptoms, according to the Asthma and Allergy Foundation of America. Many people with the condition who didn’t do well or find relief with topical steroids have had to use therapies with significant comorbidities, such as Sterapred (oral prednisone) or intramuscular prednisone, and immunomodulators such as Trexall (methotrexate) or cyclosporin, says Dr. Kwatra. “Patients had to use these therapies that had many side effects and lacked proper trials,” he says. “Medications like dupilumab, baricitinib, and other drugs in various stages of development and approval represent a new era in treating atopic dermatitis,” he adds. Baricitinib also showed efficacy in improving itch, which is a critically important measure, according to Kwatra. “Both the 1 milligram (mg) and 2 mg doses showed a four-point improvement in the itch rating scale,” he says. Baricitinib provided a four-point improvement in close to 16 percent of subjects with the 1 mg dose and in 25 percent with the 2 mg dose. The itch rating scale runs from 0 to 10, with 10 being the worst itch and 0 being no itch, explains Kwatra. “This is a very important measure, because in atopic dermatitis, itch is a driver of patient symptoms, decreased quality of life, and difficult sleeping,” he says. “Having a drop in itch severity of four points is significant.” The proportion of patients with EASI-75, the primary endpoint, and reduction in inflammatory lesions is notable as well, he adds. RELATED: Your Everyday Guide to Living Well With Eczema

More Evidence That Olumiant Is Safe for People With Atopic Dermatitis

The safety findings in the BREEZE-AD5 trial was consistent with what has been reported in other trials of the drug, according to a January 30, 2020, statement released by Eli Lilly. The most common treatment emergent adverse events (TEAE) included upper respiratory tract infections, nasopharyngitis, and diarrhea. A TEAE is an undesirable event that was not present before treatment or an already existing event or condition that worsens following the treatment. Serious blood clots, some of which have resulted in death, have been observed in other Olumiant trials, though none occurred in the BREEZE-AD5 trial. “Side effect profiles will be important to consider when the full trials come out so that we can properly educate patients,” says Kwatra. Integrating all the data along with an understanding of each patient’s preferences and comorbidities will help doctors select the right agent to treat atopic dermatitis, he adds. RELATED: Bacteria Therapy for Eczema Shows Promise for More Effective, Cheaper Treatment

Can My Doctor Prescribe Olumiant for My Atopic Dermatitis Now

Lilly has already submitted baricitinib for regulatory review in Europe as a treatment for moderate to severe atopic dermatitis and plans to submit for U.S. approval in 2020. While it is technically possible to prescribe Olumiant to patients with atopic dermatitis now, using medicines off-label is very difficult in dermatology, says Kwatra. “Off-label” is a term used when doctors decide to prescribe a U.S. Food and Drug Administration (FDA)–approved drug for an unapproved use, the FDA notes. “JAK inhibitors are being used more off-label in alopecia areata, where there’s no FDA-approved agent, but in general it’s very difficult to get off-label usage,” says Kwatra. This is because most insurance companies will not cover Olumiant for atopic dermatitis before it’s been given FDA approval for the condition, and without insurance coverage, the medication is very expensive, explains Kwatra. “I think that Olumiant will be more widely implemented for atopic dermatitis once FDA approvals are given,” he says. RELATED: A Comprehensive Glossary of Eczema Terms

When It Comes to Treating Atopic Dermatitis It s All About the Itch

A big cause of discomfort and decreased quality of life in people with atopic dermatitis is itch. “This agent, along with other agents in the pipeline and dupilumab, which is already approved for atopic dermatitis, have demonstrated abilities to affect itch, which can then result in less inflammation, less difficulty sleeping, less disruption in quality of life, and less depression and psychosocial comorbidities,” says Kwatra. “As someone who treats these patients, I really place a lot of emphasis on the itch-reduction data because it means so much in terms of what patients are experiencing on a day-to-day basis,” says Kwatra. “For that reason, I’m excited about this drug and the other drugs in the pipeline as well,” he says. NEWSLETTERS

Sign up for our Healthy Skin Newsletter

SubscribeBy subscribing you agree to the Terms of Use and Privacy Policy.

The Latest in Eczema

Atopic Dermatitis in Skin of Color Your Questions Answered

Also known as eczema, atopic dermatitis is a particular problem for Black Americans and other people of color. Mohiba Tareen, MD, a dermatologist and ...By Shantal RileySeptember 13, 2022

The Best Soap for Eczema Atopic Dermatitis Try a Non-Soap Cleanser Instead

It may be time to rethink your routine and opt for a cleanser that won’t dry out your skin like soap can. Here are 6 great picks that are gentle on eczema...By Leslie BarrieAugust 19, 2022

Eczema Treatment Topical Medication Light Therapy Natural Remedies and More

By Joseph Bennington-CastroAugust 10, 2022

Atopic Dermatitis Medications Topicals Steroids and Other Types to Know

By Joseph Bennington-CastroAugust 5, 2022

Can Mind-Body Therapies Help With Severe Eczema

These alternative approaches won’t cure your condition, but they may help you better manage its symptoms.By Blake MillerJuly 15, 2022

How to Break the Itch-Scratch Cycle if You Have Severe Eczema

The vicious cycle caused by the condition — where scratching leads to more itching — can be combatted with simple but effective methods and treatments...By Blake MillerJuly 15, 2022

6 Ways to Make Travel Easier if You Have Severe Eczema

Severe eczema doesn’t take a vacation — even when you’re traveling. Find out how to prepare for a trip and make your journey easier.By Erica PatinoJuly 15, 2022

5 Tips for Managing Anxiety and Depression if You Have Severe Eczema

Severe eczema doesn’t just cause itchy skin — it can also lead to anxiety and depression as well. Find out how to handle the emotional challenges of eczema...By Erica PatinoJuly 15, 2022

8 Ways You re Making Your Atopic Dermatitis Worse

You can’t change the genetics that underly atopic dermatitis (eczema), but you can alter the everyday behaviors that intensify itch and inflammation.By Naomi BarrJuly 13, 2022

Why Is Topical Steroid Withdrawal So Controversial in Atopic Dermatitis Treatment

Atopic dermatitis patients are taking to social media to share dramatic images of red, cracked, peeling skin that they blame on the overuse of topical...By Paula DerrowJuly 12, 2022 MORE IN

FDA Approves Dupixent Dupilumab as First Biologic Atopic Dermatitis Treatment for Kids 5 and Under

FDA Approves a First-of-Its-Kind Eczema Cream Opzelura Ruxolitinib

5 Tips for Managing Anxiety and Depression if You Have Severe Eczema

Share:
0 comments

Comments (0)

Leave a Comment

Minimum 10 characters required

* All fields are required. Comments are moderated before appearing.

No comments yet. Be the first to comment!